THE DEAL, AT A GLANCE
2/4 reviewedAnaCardio
AnaCardio
AnaCardio develops AC01, an oral drug meant to improve heart muscle pumping in heart failure.
AnaCardio raised Series B, announced 2026-09-2901What it doesAnaCardio develops AC01, an oral drug meant to improve heart muscle pumping in heart failure.Source-grounded · automated review · Explore ↗
02Who is involvedBacked by Novo Holdings, Pureos Bioventures, Sound Bioventures</strong>, Karolinska InstitutetFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedAnaCardio raised Series B, announced 2026-09-29From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersThe financing funds a Phase 2b heart-failure study planned for about 400 patients.Source-grounded · automated review · Explore ↗
Checked 2026-10-01 · Review due 2026-10-08
Read supporting source ↗The proceeds will fund AnaCardio’s…
Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗
AnaCardio · Financing Record
Explore source-linked visual explanations for AnaCardio. Unsupported claims are withheld while source review continues.
Record 13028 · Recorded date: 2026-09-29
Explore company records →